Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
99% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. PGNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PGNX' s 10-Year Cash to Debt Range
Min: 65  Med: 9999.50 Max: No Debt
Current: No Debt
Equity to Asset 0.77
PGNX's Equity to Asset is ranked higher than
61% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PGNX: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
PGNX' s 10-Year Equity to Asset Range
Min: 0.31  Med: 0.89 Max: 0.98
Current: 0.77
0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
98% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PGNX' s 10-Year Interest Coverage Range
Min: 2  Med: 10000.00 Max: 9999.99
Current: No Debt
2
9999.99
F-Score: 7
Z-Score: 7.79
M-Score: 0.60
WACC vs ROIC
17.81%
19.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 5.67
PGNX's Operating margin (%) is ranked higher than
75% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. PGNX: 5.67 )
Ranked among companies with meaningful Operating margin (%) only.
PGNX' s 10-Year Operating margin (%) Range
Min: -1033.33  Med: -91.67 Max: 35.35
Current: 5.67
-1033.33
35.35
Net-margin (%) 8.10
PGNX's Net-margin (%) is ranked higher than
77% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. PGNX: 8.10 )
Ranked among companies with meaningful Net-margin (%) only.
PGNX' s 10-Year Net-margin (%) Range
Min: -1016.67  Med: -62.54 Max: 33.31
Current: 8.1
-1016.67
33.31
ROE (%) 2.98
PGNX's ROE (%) is ranked higher than
76% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. PGNX: 2.98 )
Ranked among companies with meaningful ROE (%) only.
PGNX' s 10-Year ROE (%) Range
Min: -96.05  Med: -30.23 Max: 45.13
Current: 2.98
-96.05
45.13
ROA (%) 2.29
PGNX's ROA (%) is ranked higher than
79% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. PGNX: 2.29 )
Ranked among companies with meaningful ROA (%) only.
PGNX' s 10-Year ROA (%) Range
Min: -79.08  Med: -23.57 Max: 38.93
Current: 2.29
-79.08
38.93
ROC (Joel Greenblatt) (%) 24.62
PGNX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. PGNX: 24.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1616.79  Med: -395.31 Max: 1628.57
Current: 24.62
-1616.79
1628.57
Revenue Growth (3Y)(%) -36.40
PGNX's Revenue Growth (3Y)(%) is ranked lower than
78% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. PGNX: -36.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PGNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -55.7  Med: -16.20 Max: 73.2
Current: -36.4
-55.7
73.2
EBITDA Growth (3Y)(%) -45.50
PGNX's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. PGNX: -45.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PGNX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.5  Med: -7.00 Max: 51.4
Current: -45.5
-45.5
51.4
EPS Growth (3Y)(%) -42.20
PGNX's EPS Growth (3Y)(%) is ranked lower than
88% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. PGNX: -42.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PGNX' s 10-Year EPS Growth (3Y)(%) Range
Min: -73.5  Med: 1.30 Max: 221.4
Current: -42.2
-73.5
221.4
» PGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PGNX Guru Trades in Q2 2014

Paul Tudor Jones 2,342,388 sh (unchged)
Murray Stahl 67,200 sh (unchged)
» More
Q3 2014

PGNX Guru Trades in Q3 2014

Julian Robertson 1,290,055 sh (New)
Chuck Royce 680,000 sh (New)
Paul Tudor Jones 2,356,092 sh (+0.59%)
Murray Stahl 67,200 sh (unchged)
» More
Q4 2014

PGNX Guru Trades in Q4 2014

Jim Simons 210,698 sh (New)
Chuck Royce 1,682,850 sh (+147.48%)
Paul Tudor Jones 2,370,503 sh (+0.61%)
Murray Stahl 67,200 sh (unchged)
Julian Robertson 1,288,454 sh (-0.12%)
» More
Q1 2015

PGNX Guru Trades in Q1 2015

Chuck Royce 1,707,850 sh (+1.49%)
Murray Stahl 67,200 sh (unchged)
Julian Robertson 1,288,454 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 2,342,388 sh (-1.19%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 550.36
PGNX's P/E(ttm) is ranked lower than
96% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. PGNX: 550.36 )
Ranked among companies with meaningful P/E(ttm) only.
PGNX' s 10-Year P/E(ttm) Range
Min: 12.88  Med: 140.00 Max: 626.02
Current: 550.36
12.88
626.02
Forward P/E 54.05
PGNX's Forward P/E is ranked lower than
81% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. PGNX: 54.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 462.50
PGNX's PE(NRI) is ranked lower than
95% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. PGNX: 462.50 )
Ranked among companies with meaningful PE(NRI) only.
PGNX' s 10-Year PE(NRI) Range
Min: 12.97  Med: 143.50 Max: 462.5
Current: 462.5
12.97
462.5
P/B 4.96
PGNX's P/B is ranked lower than
57% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. PGNX: 4.96 )
Ranked among companies with meaningful P/B only.
PGNX' s 10-Year P/B Range
Min: 1.08  Med: 3.55 Max: 16.48
Current: 4.96
1.08
16.48
P/S 14.09
PGNX's P/S is ranked lower than
57% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. PGNX: 14.09 )
Ranked among companies with meaningful P/S only.
PGNX' s 10-Year P/S Range
Min: 1.92  Med: 9.80 Max: 62.55
Current: 14.09
1.92
62.55
PFCF 55.05
PGNX's PFCF is ranked lower than
60% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. PGNX: 55.05 )
Ranked among companies with meaningful PFCF only.
PGNX' s 10-Year PFCF Range
Min: 10.7  Med: 36.97 Max: 588
Current: 55.05
10.7
588
POCF 55.05
PGNX's POCF is ranked lower than
68% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. PGNX: 55.05 )
Ranked among companies with meaningful POCF only.
PGNX' s 10-Year POCF Range
Min: 10.7  Med: 35.22 Max: 267.27
Current: 55.05
10.7
267.27
EV-to-EBIT 192.38
PGNX's EV-to-EBIT is ranked lower than
92% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. PGNX: 192.38 )
Ranked among companies with meaningful EV-to-EBIT only.
PGNX' s 10-Year EV-to-EBIT Range
Min: -50.8  Med: -4.40 Max: 220.5
Current: 192.38
-50.8
220.5
Current Ratio 20.60
PGNX's Current Ratio is ranked higher than
90% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. PGNX: 20.60 )
Ranked among companies with meaningful Current Ratio only.
PGNX' s 10-Year Current Ratio Range
Min: 2.67  Med: 11.84 Max: 32.92
Current: 20.6
2.67
32.92
Quick Ratio 20.60
PGNX's Quick Ratio is ranked higher than
90% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. PGNX: 20.60 )
Ranked among companies with meaningful Quick Ratio only.
PGNX' s 10-Year Quick Ratio Range
Min: 2.67  Med: 11.84 Max: 32.92
Current: 20.6
2.67
32.92
Days Sales Outstanding 1.30
PGNX's Days Sales Outstanding is ranked higher than
97% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. PGNX: 1.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
PGNX' s 10-Year Days Sales Outstanding Range
Min: 0.9  Med: 38.99 Max: 180.24
Current: 1.3
0.9
180.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.25
PGNX's Price/Net Cash is ranked lower than
52% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. PGNX: 8.25 )
Ranked among companies with meaningful Price/Net Cash only.
PGNX' s 10-Year Price/Net Cash Range
Min: 1.59  Med: 6.10 Max: 22.41
Current: 8.25
1.59
22.41
Price/Net Current Asset Value 7.87
PGNX's Price/Net Current Asset Value is ranked lower than
53% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. PGNX: 7.87 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PGNX' s 10-Year Price/Net Current Asset Value Range
Min: 1.48  Med: 5.59 Max: 18.68
Current: 7.87
1.48
18.68
Price/Tangible Book 7.60
PGNX's Price/Tangible Book is ranked lower than
61% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. PGNX: 7.60 )
Ranked among companies with meaningful Price/Tangible Book only.
PGNX' s 10-Year Price/Tangible Book Range
Min: 1.22  Med: 4.30 Max: 13.45
Current: 7.6
1.22
13.45
Price/Median PS Value 1.52
PGNX's Price/Median PS Value is ranked lower than
65% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. PGNX: 1.52 )
Ranked among companies with meaningful Price/Median PS Value only.
PGNX' s 10-Year Price/Median PS Value Range
Min: 0.23  Med: 1.25 Max: 6.01
Current: 1.52
0.23
6.01
Price/Graham Number 7.66
PGNX's Price/Graham Number is ranked lower than
81% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. PGNX: 7.66 )
Ranked among companies with meaningful Price/Graham Number only.
PGNX' s 10-Year Price/Graham Number Range
Min: 2  Med: 4.31 Max: 12.08
Current: 7.66
2
12.08
Earnings Yield (Greenblatt) (%) 0.58
PGNX's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. PGNX: 0.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PGNX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.49  Med: 1.80 Max: 10.2
Current: 0.58
0.49
10.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PGP.Germany,
Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidates are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase 2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 26 2013 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 

More From Other Websites
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 28 2015
Trending Now: PGNX Jul 28 2015
Mid-Morning Market Update: Markets Rise; Ford Beats Q2 Estimates Jul 28 2015
Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and... Jul 28 2015
Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and... Jul 28 2015
Progenics (PGNX) Shares March Higher, Can It Continue? - Tale of the Tape Jul 22 2015
Progenics Pharmaceuticals Sets Second Quarter Financial Results Call for August 6 Jul 21 2015
Progenics Pharmaceuticals Sets Second Quarter Financial Results Call for August 6 Jul 21 2015
Moving Average Crossover Alert: Progenics Pharmaceuticals (PGNX) - Tale of the Tape Jul 09 2015
Is Progenics Pharmaceuticals (PGNX) Stock a Solid Choice Right Now? - Tale of the Tape Jul 09 2015
Progenics Pharmaceuticals Announces Plans to Move Forward With 1404 Phase 3 Trial Jul 07 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 07 2015
Progenics Pharmaceuticals Announces Plans to Move Forward With 1404 Phase 3 Trial Jul 07 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 02 2015
Needham Is Bullish On Progenics Pharmaceuticals Jun 25 2015
Valeant-Progenics Report NDA Filing for Oral Relistor in US - Analyst Blog Jun 24 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2015
Progenics Pharmaceuticals to Present at Cantor Fitzgerald's Inaugural Healthcare Conference Jun 24 2015
Progenics Pharmaceuticals to Present at Cantor Fitzgerald's Inaugural Healthcare Conference Jun 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK